Biochemistry and Genetics Pretesttmself-Assessment and Review Notice

Total Page:16

File Type:pdf, Size:1020Kb

Biochemistry and Genetics Pretesttmself-Assessment and Review Notice Biochemistry and Genetics PreTestTMSelf-Assessment and Review Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example, and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Biochemistry and Genetics PreTestTMSelf-Assessment and Review Third Edition Golder N. Wilson MD, PhD Clinical Professor, Texas Tech University KinderGenome Pediatric Genetics, Dallas, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Manufactured in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher. 0-07-150936-4 The material in this eBook also appears in the print version of this title: 0-07-147183-9. All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the ben- efit of the trademark owner, with no intention of infringement of the trademark. Where such desig- nations appear in this book, they have been printed with initial caps. McGraw-Hill eBooks are available at special quantity discounts to use as premiums and sales pro- motions, or for use in corporate training programs. For more information, please contact George Hoare, Special Sales, at [email protected] or (212) 904-4069. TERMS OF USE This is a copyrighted work and The McGraw-Hill Companies, Inc. (“McGraw-Hill”) and its licen- sors reserve all rights in and to the work. Use of this work is subject to these terms. Except as per- mitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill’s prior consent. You may use the work for your own noncommercial and per- sonal use; any other use of the work is strictly prohibited. Your right to use the work may be termi- nated if you fail to comply with these terms. THE WORK IS PROVIDED “AS IS.” McGRAW-HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETE- NESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill and its licensors do not warrant or guar- antee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill nor its licensors shall be liable to you or any- one else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such dam- ages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise. DOI: 10.1036/0071471839 Professional Want to learn more? We hope you enjoy this McGraw-Hill eBook! If you’d like more information about this book, its author, or related books and websites, please click here. Student Reviewers Daniel Krochmal University of Michigan Medical School Class of 2006 Sunitha J. Moonthungal St. George’s University Class of 2006 David Scoville University of Kansas School of Medicine Class of 2008 This page intentionally left blank For more information about this title, click here Contents Preface. ix Introduction . x Note Concerning Disease Examples . xi Abbreviations . xii High-Yield Facts High-Yield Facts in Biochemistry and Genetics . 1 STORAGE AND EXPRESSION OF GENETIC INFORMATION DNA Structure, Replication, and Repair Questions . 59 Answers . 75 Gene Expression and Regulation Questions . 93 Answers . 119 ACID-BASE EQUILIBRIA,AMINO ACIDS, AND PROTEIN STRUCTURE/FUNCTION Acid-Base Equilibria,Amino Acids, and Protein Structure Questions . 147 Answers . 163 Protein Structure/Function Questions . 183 Answers . 196 vii viii Contents INTERMEDIARY METABOLISM Carbohydrate Metabolism Questions . 209 Answers . 223 Bioenergetics and Energy Metabolism Questions . 239 Answers . 251 Lipid,Amino Acid, and Nucleotide Metabolism Questions . 263 Answers . 284 NUTRITION Vitamins and Minerals Questions . 309 Answers . 320 Hormones and Integrated Metabolism Questions . 337 Answers . 351 INHERITANCE MECHANISMS AND BIOCHEMICAL GENETICS Inheritance Mechanisms/Risk Calculations Questions . 373 Answers . 395 Genetic and Biochemical Diagnosis Questions . 419 Answers . 442 Bibliography . 469 Appendix . 471 Index . 485 Preface The new edition of Biochemistry and Genetics PreTest: Self-Assessment and Review is based in part on earlier editions prepared by Golder N. Wilson, MD, PhD, Department of Pediatrics, Texas Tech University Health Sciences Center, Cheryl Ingram-Smith, PhD, and Kerry S. Smith, PhD, Department of Genetics, Biochemistry, and Life Science Studies Clemson University Clemson, South Carolina, and by Francis J. Chlapowski, PhD, Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School. All questions are in single-best-answer format and a large number are analogous to those of the United States Medical Licensing Examination (USMLE), Step 1. Questions are updated to the most current editions of leading textbooks in medical biochemistry and medical genetics. ix Copyright © 2007 by The McGraw-Hill Companies, Inc. Click here for terms of use. Introduction Each PreTest Self-Assessment and Review allows medical students to com- prehensively and conveniently assess and review their knowledge of a par- ticular basic science, in this instance biochemistry and genetics. The 500 questions parallel the format and degree of difficulty of the questions found in the United States Medical Licensing Examination (USMLE) Step 1. The Appendix lists subjects from the USMLE guidelines and shows the relevant question numbers from this PreTest book that relate to these subjects. Each question is accompanied by an answer, a paragraph explanation, and a specific page reference to an appropriate textbook. A bibliography listing sources can be found at the end of this text, and a list of abbrevia- tions used in the text follows this introduction. Over 200 clinical disorders or processes are discussed and related to biochemical and/or genetic mech- anisms (see the appendix for a list of disease examples). For genetic disor- ders, a McKusick number is included that allows the reader to immediately access information about the disorder using the Online Mendelian Inheri- tance in Man Internet site (http://www.ncbi.nlm.nih.gov/omim/). An effective way to use this PreTest is to allow yourself 1 minute to answer each question in a given chapter. As you proceed, indicate your answer beside each question. By following this suggestion, you approxi- mate the time limits imposed by the USMLE Step 1 examination. After you finish going through the questions in the section, spend as much time as you need verifying your answers and carefully reading the explanations provided. Pay special attention to the explanations for the questions you answered incorrectly—but read every explanation. The authors of this material have designed the explanations to reinforce and supplement the information tested by the questions. If you feel you need further informa- tion about the material covered, consult and study the text or online refer- ences indicated. The high-yield facts in this book are provided to facilitate rapid review of biochemistry and genetics. Key concepts and diagrams are arranged before each section, and it is anticipated that the reader will use the key concepts as a “memory jog” before proceeding through the questions. x Copyright © 2007 by The McGraw-Hill Companies, Inc. Click here for terms of use. Note Concerning Disease Examples This book provides over 130 disease examples (see Appendix) to illustrate the broad application of biochemistry and genetics to medicine. These include more common chromosomal or multifactorial disorders (Down syndrome, cleft palate, diabetes mellitus) that have incidences ranging from 1 in 200 to 1 in 2000–3000 to less common single gene disorders (cystic fibrosis, glycogen storage diseases) with incidences of 1 in 1600 to 1 per million individuals).
Recommended publications
  • Phosphorylation of Mcardle Phosphorylase Induces Activity (Human Skeletal Muscle/Protein Kinase) CESARE G
    Proc. Nati. Acad. Sci. USA Vol. 78, No. 5, pp. 2688-2692, May 1981 Biochemistry Phosphorylation of McArdle phosphorylase induces activity (human skeletal muscle/protein kinase) CESARE G. CERRI AND JOSEPH H. WILLNER Department of Neurology and H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032 Communicated by Harry Grundfest, January 7, 1981 ABSTRACT In McArdle disease, myophosphorylase defi- mediate between those of phosphorylases b and a. Karpatkin ciency, enzyme activity is absent but the presence of an altered et al. (19, 20) found that incubation of human platelets with enzyme protein can frequently be demonstrated. We have found MgATP+ resulted in an increase in total phosphorylase activity that phosphorylation of this protein in vitro can result in catalytic and concluded that the data were "consistent with the presence activity. We studied muscle of four patients; all lacked myophos- in human platelets of inactive dimer and monomer species of phorylase activity, but myophosphorylase protein was demon- phosphorylase, which require MgATP for activation." Because strated by immunodiffusion or gel electrophoresis. Incubation of activation of these isozymes was probably due to protein phos- muscle homogenate supernatants with cyclic AMP-dependent pro- phorylation and also because incomplete phosphorylation could tein kinase and ATP resulted in phosphorylase activity. The ac- tivated enzyme comigrated with normal human myophosphory- result in reduced activity, we evaluated the possibility that the lase in gel electrophoresis. Incubation with [y-32P]ATP resulted activity ofphosphorylase in McArdle muscle could be restored in incorporation of 32P into the band possessing phosphorylase by phosphorylation of the inactive phosphorylase protein pres- activity.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • Statistical Mechanics of Allosteric Enzymes
    Statistical Mechanics of Allosteric Enzymes Tal Einav,† Linas Mazutis,‡ and Rob Phillips∗,¶ Department of Physics, California Institute of Technology, Pasadena, California 91125, United States, Institute of Biotechnology, Vilnius University, Vilnius, Lithuania, and Department of Applied Physics and Division of Biology, California Institute of Technology, Pasadena, California 91125, United States E-mail: [email protected] Abstract The concept of allostery in which macromolecules switch between two different conforma- tions is a central theme in biological processes ranging from gene regulation to cell signaling to enzymology. Allosteric enzymes pervade metabolic processes, yet a simple and unified treatment of the effects of allostery in enzymes has been lacking. In this work, we take the first step towards this goal by modeling allosteric enzymes and their interaction with two key molecular players - allosteric regulators and competitive inhibitors. We then apply this model to characterize existing data on enzyme activity, comment on how enzyme parameters (such as substrate binding affinity) can be experimentally tuned, and make novel predictions on how to control phenomena such as substrate inhibition. arXiv:1701.03988v1 [q-bio.SC] 15 Jan 2017 ∗To whom correspondence should be addressed †Department of Physics, California Institute of Technology, Pasadena, California 91125, United States ‡Institute of Biotechnology, Vilnius University, Vilnius, Lithuania ¶Department of Applied Physics and Division of Biology, California Institute
    [Show full text]
  • Lec-08-Handout
    NPTEL VIDEO COURSE – PROTEOMICS PROF. SANJEEVA SRIVASTAVA HANDOUT LECTURE-08 ENZYME: BASIC CONCEPTS, CATALYTIC AND REGULATORY STRATEGIES Slide 1 Today, we will talk about enzyme: basic concepts, catalytic and regulatory strategies. Slide 2 Lecture outline: • Basic concepts of enzyme including enzyme kinetics, energetics and enzyme inhibition. • Different type of catalytic strategies and regulatory strategies. Slide 3 So as you all know, enzymes play very important role in biochemistry All enzymes are proteins therefore it will essential to study about enzymes while studying basic concepts of amino acids and proteins. Although it may not be directly linked to the proteomics but understanding of enzyme and proteins is very fundamental for the advanced understanding of concepts related to proteomics. Slide 4 So what are enzymes? • Enzymes are molecular catalysts. • Almost all enzymes are proteins and as we have discussed in the previous lecture there are twenty amino acids that make up the basic building blocks of all proteins. • Enzymes can accelerate a given reaction up to million folds. Let’s take an example of carbonic anhydrase which catalyzes hydration of carbon di oxide. Now this enzyme can catalyze 106 molecules per second. • Enzymes are highly specific and catalyze single or closely related reaction. DEPARTMENT OF BIOSCIENCES & BIOENGINEERING INDIAN INSTITUTE OF TECHNOLOGY (IIT) BOMBAY, MUMBAI, INDIA Page 1 NPTEL VIDEO COURSE – PROTEOMICS PROF. SANJEEVA SRIVASTAVA Slide 5 In terms of enzyme specificity, let me give you few examples- • Trypsin- it is highly specific, it cleaves peptide on carboxyl side of Lys/Arg. • Another enzyme thrombin, which participates in blood clotting, it is even more specific that trypsin.
    [Show full text]
  • Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide
    ICANCER RESEARCH 26 Part 1, 1466-1472,July 1966] Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide Treatment on the in Vitro Activity of the Deoxyribonucleic Acid Synthetase System of Sensitive and Resistant Plasmacytomas1 ARTHUR J. TOMISEK, MARTHA BRUCE IRICK, AND PAULA WEDELES ALLAN Kettering'-Meyer Laboratory,2 Southern Research Institute, Birmingham, Alabama Summary term DNA-synthetase. In addition to this measurement of over-all DNA synthetase activity, we used the same experiments We have shown that the in vivo treatment of Fortner plasma- to determine the time course of radioactivity distribution among cytomas with Cyclophosphamide can lead to strong inhibitions of both deoxyribonucleic acid nucleotidyl transferase and thymi- the soluble components of the synthetase reaction mixtures. Our data show that the observed decreases in enzyme activity dylatc kinase activities in the soluble cell fractions. However, in are among the possible consequences of growth inhibition in the allowing only 2 hr for the inhibitor to act, the effect observed on tumor. the transferase was an unexplained stimulation rather than an inhibition. We have also provided some evidence that the inhibition of Materials and Methods growth precedes the inhibition of deoxyribonucleic acid nucleo ENZYME PREPARATION.Fortner hamster plasmacytoma tidyl transferase activity. ("sensitive") (3) and ite cyclophosphamide-resistant subline (12) were used for bilateral s.c. implantation into groups of 6-12 Introduction Golden Syrian hamsters, the animals in each experiment being uniform with respect to commercial subline, sex, and approxi Previous studies in this laboratory have shown that several mate age. On the 12th-14th postimplant day the animals were alkylating agents inhibited the in vivo synthesis of DNA by divided into 2 subgroups, to receive daily i.p.
    [Show full text]
  • WO 2013/153359 Al 17 October 2013 (17.10.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/153359 Al 17 October 2013 (17.10.2013) P O P C T (51) International Patent Classification: Edmund Cartwright House, 4 Robert Robinson Avenue, C07K 14/435 (2006.01) C12Q 1/00 (2006.01) Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB). (21) International Application Number: (74) Agent: CHAPMAN, Lee Phillip; 14 South Square, Gray's PCT/GB20 13/050667 Inn, London Greater London WC1R 5JJ (GB). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 15 March 2013 (15.03.2013) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (30) Priority Data: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 61/622,174 10 April 2012 (10.04.2012) US ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (71) Applicant: OXFORD NANOPORE TECHNOLOGIES NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, LIMITED [GB/GB]; Edmund Cartwright House, 4 Robert RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, Robinson Avenue, Oxford Science Park, Oxford Oxford TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, shire OX4 4GA (GB).
    [Show full text]
  • (Glycogen Storage Disease Type V) and Anesthesia a Case Report And
    Pediatric Anesthesia ISSN 1155-5645 REVIEW ARTICLE McArdle’s disease (glycogen storage disease type V) and anesthesia – a case report and review of the literature Georg Bollig1,2 1 Department of Anesthesiology and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, Schleswig, Germany 2 Department of Surgical Sciences, Haukeland University Hospital, University of Bergen, Bergen, Norway Keywords Summary general anesthesia; glycogen storage disease; glycogen storage disease type V; McArdles disease (glycogen storage disease type v) is a rare condition in malignant hyperthermia; McArdles disease; which energy-metabolism in the muscle is hampered. A case report is pre- perioperative complications sented and the possible risk for perioperative complications including malig- nant hyperthermia is discussed. A checklist for the anesthesiological Correspondence management of patients with McArdles disease is provided. A short overview Georg Bollig, Department of Anesthesiology of anesthesiological challenges and perioperative complications of other gly- and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, cogen storage diseases is given. Schleswig, Germany Email: [email protected] Section Editor: Barbara Brandom Accepted 3 March 2013 doi:10.1111/pan.12164 tachycardia and hypotonia occurred. After the opera- Introduction tion, the anesthesiologist informed the patient about the McArdle’s disease is a rare condition in which energy event and the fact that he had elevated liver enzymes metabolism in the muscle is hampered. A case report (aspartate transaminase = AST, alanine transaminase = will be presented, and the possible risk of perioperative ALT, and lactate dehydrogenase = LDH). An overview problems including malignant hyperthermia is dis- of the patient’s anesthesiological history is given in cussed.
    [Show full text]
  • Hemoglobin : Its Protein of Molecular Weight 64,450 , in Human Beings It
    Hemoglobin : its protein of molecular weight 64,450 , in human beings it is enclose in the RBC .if it were in plasma, some of it leaks through the capillary membrane into the tissue space or through the glomerular membrane of the kidney into the glomerular filtrate each time the blood passes through the capillaries , high free plasma concentration of Hb increased blood viscosity and osmotic pressure. So for Hb to remain in the bloodstream , it must exist in the RBCs ,its major function is to carry O2 to the tissue and also it transport CO2 from the tissues to the lungs Normal hemoglobin type: Hb A: Its normal adult Hb . Its molecule consist of four polypeptide chains ,2 alpha (α) chains (each of which contains 141 amino acids) and 2 beta chains (each of which contains 146 amino acids).thus Hb A is designated α2 and β2. Hb A is predominant type of Hb in adult (95- 97% of total Hb) . Hb A2 : in the normal adult about 25% of the total Hb is Hb A2 in which chain are replaced by delta chains and is designated 2 α 2δ2 . Each δ chain also contain 146 amino acid but 10 amino acid differ from those in the β chain . Hb F (Fetal Hb): it is the main Hb in fetus and new born . It is 2α 2γ,gamma(γ) chain also has 146 amino acid but 37 amino acid differ from those in β chain, Hb F is replaced gradually by adult Hb soon after birth, usually at about 6 months to one year of age, the normal adult Hb predominates .
    [Show full text]
  • Metabolic Stable Isotope Fractionation
    Photograph by author, Gina M.A. Carroll Metabolic Stable Isotope Fractionation: Biogeochemical Approaches to Diagnosing Sickle Cell and Thalassemia Anemia in the Archaeological Record MSc Thesis Faculty of Archaeology MSc Proefschrift Faculteit der Archaeologie Gina M.A. Carroll 1 Photograph by Gina. M.A. Carroll Taken with permission from the Municipal Museum of Écija, Spain April 2014 Gina M.A. Carroll Alberta, Canada Leiden, The Netherlands [email protected] 1 Metabolic Stable Isotope Fractionation: Biogeochemical Approaches to Diagnosing Sickle Cell and Thalassemia Anemia in the Archaeological Record. MSc Thesis MSc Proefschrift Gina M.A. Carroll Human Osteology and Funerary s1371266 Archaeology MSc Thesis Archaeology University of Leiden Faculty of Archaeology ARCH 1044WY Prof. Dr. Waters-Rist Leiden, The Netherlands & Prof. Dr. Inskip Leiden, 26 May 2015 Final Draft. 2 TABLE OF CONTENTS DEDICATIONS ...................................................................................................................... 9 ACKNOWLEDGEMENTS .................................................................................................. 10 CHAPTER 1 INTRODUCTION ....................................................................... 12-30 1. BRIEF HISTORY OF ARCHAEOLOGICAL RESEARCH ........................................ 13 1.1. The Anemias in Archaeology ....................................................... 14 1.2. The Application of Stable Isotopes in Palaeopathology ............... 18 2. HYPOTHESIS ................................................................................................
    [Show full text]
  • Structure and Evolution of Protein Allosteric Sites
    Structure and evolution of protein allosteric sites by Alejandro Panjkovich Thesis submitted to Universitat Aut`onoma de Barcelona in partial fulfillment of the requirements for the degree of Doctor of Philosophy Director - Prof. Xavier Daura Tesi Doctoral UAB/ANY 2013 Ph.D. Program - Protein Structure and Function Institut de Biotecnologia i Biomedicina caminante, no hay camino, se hace camino al andar Antonio Machado,1912 Acknowledgements First of all I would like to thank my supervisor and mentor Prof. Xavier Daura for his consistent support and trust in my work throughout these years. Xavi, I deeply appreciate the freedom you gave me to develop this project while you were still carefully aware of the small details. Working under your supervision has been a rich and fulfilling experience. Of course, thanks go as well to current and past members of our institute, especially Rita Rocha, Pau Marc Mu˜noz,Oscar Conchillo, Dr. Mart´ınIndarte, Dr. Mario Ferrer, Prof. Isidre Gibert, Dr. Roman Affentranger and Dr. Juan Cedano for their technical and sometimes philo- sophical assistance. Help from the administrative staff was also significant, I would like to thank in particular Eva, Alicia and Miguel who where always ready to help me in sorting out unexpected bureaucratic affairs. I would also like to thank Dr. Mallur Srivatasan Madhusudhan and his group (especially Kuan Pern Tan, Dr. Minh Nguyen and Binh Nguyen), and also Dr. Gloria Fuentes, Cassio Fernandes, Youssef Zaki, Thijs Kooi, Rama Iyer, Christine Low and many others at the Bioinformatics Institute BII - A∗STAR in Singapore for the many interesting discussions and support during my stage over there.
    [Show full text]
  • Guaiacol As a Drug Candidate for Treating Adult Polyglucosan Body Disease
    Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon, … , Wyatt W. Yue, H. Orhan Akman JCI Insight. 2018;3(17):e99694. https://doi.org/10.1172/jci.insight.99694. Research Article Metabolism Therapeutics Graphical abstract Find the latest version: https://jci.me/99694/pdf RESEARCH ARTICLE Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon,1 Igor Ferreira,2 Leonardo J. Solmesky,3 Netaly Khazanov,4 Alexander Lossos,1 Rafael Alvarez,5 Deniz Yetil,6 Sergey Pampou,7 Miguel Weil,3,8 Hanoch Senderowitz,4 Pablo Escriba,5 Wyatt W. Yue,2 and H. Orhan Akman9 1Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.3 Cell Screening Facility for Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 4Department of Chemistry, Bar Ilan University, Ramat Gan, Israel. 5Laboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain. 6Connecticut College, Newington, Connecticut USA. 7Columbia University Department of Systems Biology Irving Cancer Research Center, New York, New York, USA. 8Laboratory for Neurodegenerative Diseases and Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty for Life Sciences, Sagol School of Neurosciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 9Columbia University Medical Center Department of Neurology, Houston Merritt Neuromuscular diseases research center, New York, New York, USA. Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency.
    [Show full text]
  • Published on May 14, 2008 As Doi: 10.1183/09031936.00126507 ERJ
    ERJ Express. Published on May 14, 2008 as doi: 10.1183/09031936.00126507 ACCURACY AND RELIABILITY OF PULSE OXIMETRY AT DIFFERENT PaCO2 LEVELS Authors: Muñoz Xa,b,d , Torres Fc , Sampol Ga,d , Rios Jc , Martí Sa,d , Escrich Eb a) Servei de Pneumologia,Hospital Universitari Vall d’Hebron, Barcelona, Spain b) Departament de Biología Cel·lular, de Fisiologia i d’Immunologia, UAB, Barcelona, Spain c) Laboratorio de Bioestadística i Epidemiología (Universitat Autònoma de Barcelona); Servei de Farmacologia Clínica, IDIBAPS, (Hospital Clínic), Barcelona d) CIBER de Enfermedades Respiratorias (Ciberes) Correspondence to: Dr. Xavier Muñoz Servei de Pneumologia Hospital Vall d'Hebron Pº Vall d'Hebron, 119-129 08035 Barcelona Spain Telf: 00 34 93 2746157 Fax: 00 34 93 2746083 E-mail: [email protected] Short title: ACCURACY OF PULSE OXIMETRY AND PaCO2 LEVELS The first two authors have contributed equally to this study. Copyright 2008 by the European Respiratory Society. ABSTRACT Aim: To assess whether arterial carbon dioxide pressure (PaCO2) has an impact on agreement between oxygen saturation measured with pulse oximetry (SpO2) or arterial blood gas co- oximetry (SaO2). Methods: A study was performed on SaO2 and SpO2 determinations obtained simultaneously from 846 patients under assessment for long-term home oxygen therapy in a specialized outpatient clinic. Both measurements were taken with patients seated and breathing room air. Agreement between SaO2 and SpO2 results was analyzed by the Bland-Altman method and the Lin concordance coefficient. In addition, potential interactions of PaO2 or PaCO2 on agreement were analyzed by adjusted multivariate analysis. Results: At comparison of SaO2 and SpO2 results, the Bland-Altman technique yielded a bias (95% CI) of -1.24 (-6.86; 4.38) and -1.32 (-7.78; 5.15) when PaCO2 was higher than 48 mmHg or PaO2 lower than 54 mmHg, respectively.
    [Show full text]